Rice Hall James & Associates LLC Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rice Hall James & Associates LLC increased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 579.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 362,893 shares of the company's stock after purchasing an additional 309,518 shares during the period. Rice Hall James & Associates LLC owned approximately 0.44% of Viridian Therapeutics worth $4,892,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Bank of New York Mellon Corp increased its position in Viridian Therapeutics by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 198,177 shares of the company's stock worth $2,671,000 after purchasing an additional 1,655 shares during the last quarter. Principal Financial Group Inc. increased its position in Viridian Therapeutics by 17.0% in the first quarter. Principal Financial Group Inc. now owns 208,836 shares of the company's stock worth $2,815,000 after purchasing an additional 30,392 shares during the last quarter. Amalgamated Bank increased its position in Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after purchasing an additional 840 shares during the last quarter. SG Americas Securities LLC increased its position in Viridian Therapeutics by 2.9% in the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after purchasing an additional 887 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Viridian Therapeutics by 4.6% in the first quarter. Rhumbline Advisers now owns 104,559 shares of the company's stock worth $1,409,000 after purchasing an additional 4,621 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on VRDN. The Goldman Sachs Group reduced their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. JMP Securities dropped their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada dropped their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $37.56.

Viridian Therapeutics Trading Up 1.5%

Shares of VRDN traded up $0.26 during trading hours on Thursday, reaching $17.05. 419,240 shares of the company traded hands, compared to its average volume of 1,137,856. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -4.43 and a beta of 0.39. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The company has a current ratio of 19.49, a quick ratio of 19.49 and a debt-to-equity ratio of 0.05. The stock's fifty day moving average price is $14.72 and its 200 day moving average price is $15.39.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. The firm's quarterly revenue was up .0% compared to the same quarter last year. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.